Yamamoto Daigo, Yamamoto Chizuko, Okugawa Homa, Tsubota Yu, Kawakami Katsuhiro
Dept. of Surgery, Seiko Hospital.
Gan To Kagaku Ryoho. 2021 Mar;48(3):455-456.
Breast cancer patient(invasive ductal carcinoma, ER[+], PgR[+], HER2[3+], Ki-67: 30%)had neoadjuvant chemotherapy( FEC followed by docetaxel plus trastuzumab). After surgical operation(mastectomy and Ax)was performed and she received trastuzumab plus hormone therapy. After 2 years later, she had liver metastasis that showed IDC, ER(+), PgR (+), HER2(-). In addition, BRCA positive was shown. Therefore, the patient received olaparib tablets(300 mg twice daily). After 2 months later, liver metastasis reduced dramatically.
乳腺癌患者（浸润性导管癌，雌激素受体[ER][+]，孕激素受体[PgR][+]，人表皮生长因子受体2[HER2][3+]，Ki-67：30%）接受了新辅助化疗（FEC方案序贯多西他赛加曲妥珠单抗）。手术（乳房切除术和腋窝清扫术）后，她接受了曲妥珠单抗加激素治疗。两年后，她出现肝转移，病理显示为浸润性导管癌，ER(+)，PgR(+)，HER2(-)。此外，检测显示BRCA呈阳性。因此，该患者接受了奥拉帕利片治疗（每日两次，每次300毫克）。两个月后，肝转移灶显著缩小。
